
Inscripta
Founded Year
2015Stage
Series E - II | AliveTotal Raised
$413.69MLast Raised
$100M | 1 yr agoAbout Inscripta
Inscripta develops a benchtop platform for scalable digital genome engineering. The company's CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables parallel, trackable editing of single cells at scale.
Inscripta Headquarter Location
5500 Central Avenue Suite 220
Boulder, Colorado, 80301,
United States
(720) 759-4088
Research containing Inscripta
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Inscripta in 1 CB Insights research brief, most recently on Dec 11, 2019.
Expert Collections containing Inscripta
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Inscripta is included in 3 Expert Collections, including Synthetic Biology.
Synthetic Biology
238 items
Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.
Biopharma Tech
5,241 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Omics
1,265 items
Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data
Inscripta Patents
Inscripta has filed 185 patents.
The 3 most popular patent topics include:
- Molecular biology
- Biotechnology
- Genetics
Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
12/17/2021 | 5/17/2022 | Molecular biology, Genetics, Biotechnology, DNA, Molecular genetics | Grant |
Application Date | 12/17/2021 |
---|---|
Grant Date | 5/17/2022 |
Title | |
Related Topics | Molecular biology, Genetics, Biotechnology, DNA, Molecular genetics |
Status | Grant |
Latest Inscripta News
May 18, 2022
Paul Schloesser Associate Editor Earlier this year, Moderna and nonprofit research group IAVI (International AIDS Vaccine Initiative) announced that the first doses of an mRNA anti-HIV vaccine candidate had been administered in a trial called IAVI G002. That was, at least somewhat, in line with Moderna CEO Stéphane Bancel’s goal for the company last year to launch three Phase I trials for an HIV program. Based on results from studies in previous years (G001 launched in 2018), Moderna and IAVI are now jumping into a new collaborative trial: IAVI G003, a Phase I trial that IAVI will sponsor. Moderna said early Wednesday that participant screenings are starting soon for the biotech’s mRNA HIV vaccine antigen in two places: Rwanda and South Africa. The biotech said that the new study builds off of results from IAVI G001, another Phase I trial which, according to Moderna, showed that vaccination safely brought out an immune response in 97% of healthy, US adults. The goal for this new study? To see if the immune response from the first trial — in an American population — will translate and bring a similar immune response in the new study’s African population. Moderna listed several sponsors behind the study, including the US’ President’s Emergency Plan for AIDS Relief (PEPFAR) through USAID and the Bill & Melinda Gates Foundation through various grants. Bancel said in a statement that “Moderna’s HIV vaccine development program, together with our portfolio of Covid-19, Zika, and Nipah programs, advances 4 of the 15 priority vaccine programs we committed to develop by 2025.” According to the biotech, trial sites are expected to enroll a combined total of 18 healthy, HIV-negative adult volunteers for IAVI G003, which will not be blinded or randomized. All participants will receive two doses of the candidate and then be monitored for six months, and the primary endpoints will be safety and immunogenicity. This is Moderna’s newest step toward Africa after the biotech entered a memorandum of understanding with the Kenyan government earlier this year for its first manufacturing facility on the continent. Moderna’s efforts in the HIV space are just one of several attempts being made to go after what was once considered a death sentence. Biotech and pharma alike have been engaging in research to try to cure the disease for good through various mitigation and prophylactic measures. Newer focuses include Gilead’s experimental lenacapavir or testing already-approved drugs with potential, such as a study published in Science Translational Medicine back in January that looked at Keytruda with some optimism. Max Gelman Senior Editor Since the first experimental Duchenne gene therapy programs came about, the space has proven rife with safety issues and patient deaths in clinical trials. Pfizer and three biotechs now think they’ve found a reason why. The four companies suggested there may be a “class effect” causing the adverse events in Duchenne gene therapies, they wrote in a new study. They specifically highlighted how side effects in five patients across three trials, who all showed muscle weakness with cardiac involvement, were “strikingly similar.” Keep reading Endpoints with a free subscription Unlock this story instantly and join 142,300+ biopharma pros reading Endpoints daily — and it's free. SIGN UP John Carroll Editor & Founder Flagship has crafted a new startup out of pieces from a pair of fledglings in the VC’s nest. And a prominent Roche veteran who ran one of the biotechs won’t be making the next leg of the journey. The new company is called Sonata Therapeutics, which is picking up the work that Inzen was doing related to the cellular microenvironment and combining with Flagship’s Cygnal Therapeutics, which came out of stealth more than 3 years ago and put Pearl Huang — the BeiGene founder and former Roche SVP — at the helm. Keep reading Endpoints with a free subscription Unlock this story instantly and join 142,300+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Tyler Patchen News Reporter The story of Henrietta Lacks’ immortal cell line and her family’s fight for justice caught the attention of national media outlets and Hollywood years ago. Now, the case faces an uncertain fate as a Baltimore federal judge considers tossing the case. After a hearing on Tuesday, Judge Deborah Boardman is weighing Thermo Fisher’s motion to dismiss the claims against it on the grounds that the statute of limitations has passed, and the continuing harm doctrine does not apply. Boardman is grappling with the “extraordinarily unique facts” of the case, according to Maryland Matters, which first reported the news. Read More Tyler Patchen News Reporter Vertex Pharmaceuticals has been one of the buzzier names in the bustling Boston biotech scene, but now the company is looking to vault to number one status — at least in terms of physical footprint. At a ribbon cutting on Tuesday for its new Jeffrey Leiden Center for Cell and Genetic Therapies at the Boston Seaport, Vertex announced it would embark on a new project: The company will build a 344,000 square foot facility in the seaport to accommodate the company’s growing R&D needs, especially in its cell and gene therapies program. Keep reading Endpoints with a free subscription Unlock this story instantly and join 142,300+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Tyler Patchen News Reporter A plan to broaden access to CRISPR has attracted a chunk of funding and is now seeing its wings spread. Fargo-based DNA and mRNA producer Aldevron has signed an agreement with life sciences company Inscripta to manufacture and commercialize the Eureca-V Nuclease, a wild-type MAD7 CRISPR Type-V nuclease. This partnership will aim to offer this nuclease as a standard research-grade and GMP catalog item. According to a press release, the production of Eureca-V is slated to start in Q3 of 2022. Financial details of the deal were not immediately made available to Endpoints News. Read More
Inscripta Web Traffic
Inscripta Rank
When was Inscripta founded?
Inscripta was founded in 2015.
Where is Inscripta's headquarters?
Inscripta's headquarters is located at 5500 Central Avenue, Boulder.
What is Inscripta's latest funding round?
Inscripta's latest funding round is Series E - II.
How much did Inscripta raise?
Inscripta raised a total of $413.69M.
Who are the investors of Inscripta?
Investors of Inscripta include Foresite Capital, Fidelity Investments, D1 Capital Partners, Morgan Stanley, T. Rowe Price and 12 more.
Who are Inscripta's competitors?
Competitors of Inscripta include Mammoth Biosciences.
You May Also Like

Sherlock leverages engineering biology tools, including CRISPR and Synthetic Biology, to create a new generation of molecular diagnostics that can rapidly deliver accurate results for a range of needs in virtually any setting. The company is developing applications of SHERLOCK, a CRISPR-based method to detect and quantify specific genetic sequences, and INSPECTR, a Synthetic Biology-based molecular diagnostics platform that is instrument free. SHERLOCK and INSPECTR can be used in virtually any setting without complex instrumentation, opening up a wide range of potential applications in areas including precision oncology, infection identification, food safety, at-home tests, and disease detection in the field.

Mammoth Biosciences develops CRISPR systems and aims to democratize disease detection with a point-of-care test that allows for rapid and simultaneous detection of multiple conditions.

Arbor Biosciences is a biotech company specializing in custom, affordable solutions for synthetic biology and NGS target enrichment.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.